Trial Profile
Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Baricitinib (Primary) ; Methotrexate (Primary) ; Sulfasalazine (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacodynamics
- Acronyms SurviTreat
- 03 May 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2025.
- 03 May 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2025.
- 12 May 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.